CRIS Current Research Information System

CAVO, MICHELE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 24.082
EU - Europa 16.024
AS - Asia 9.569
AF - Africa 1.033
SA - Sud America 68
Continente sconosciuto - Info sul continente non disponibili 41
OC - Oceania 41
Totale 50.858
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 23.983
GB - Regno Unito 4.412
IT - Italia 3.285
CN - Cina 3.111
SG - Singapore 2.634
SE - Svezia 2.227
DE - Germania 2.170
VN - Vietnam 2.134
IN - India 1.059
IE - Irlanda 792
RU - Federazione Russa 624
FR - Francia 615
UA - Ucraina 506
TG - Togo 365
ZA - Sudafrica 324
EE - Estonia 312
BG - Bulgaria 207
CI - Costa d'Avorio 193
FI - Finlandia 188
JO - Giordania 184
CH - Svizzera 163
ID - Indonesia 123
BE - Belgio 119
NG - Nigeria 107
NL - Olanda 93
CA - Canada 90
JP - Giappone 64
AT - Austria 63
IR - Iran 58
HK - Hong Kong 50
ES - Italia 41
PL - Polonia 40
AU - Australia 37
EU - Europa 36
SC - Seychelles 30
TR - Turchia 30
GR - Grecia 29
LB - Libano 27
CL - Cile 24
BR - Brasile 23
RO - Romania 23
CZ - Repubblica Ceca 22
LT - Lituania 20
HR - Croazia 15
PH - Filippine 15
UZ - Uzbekistan 14
KR - Corea 12
AR - Argentina 10
EG - Egitto 10
IL - Israele 9
NO - Norvegia 9
RS - Serbia 9
DK - Danimarca 8
PT - Portogallo 8
TW - Taiwan 8
A2 - ???statistics.table.value.countryCode.A2??? 5
BD - Bangladesh 5
HU - Ungheria 5
SA - Arabia Saudita 5
AL - Albania 4
EC - Ecuador 4
MY - Malesia 4
NZ - Nuova Zelanda 4
PK - Pakistan 4
BZ - Belize 3
IQ - Iraq 3
MK - Macedonia 3
PE - Perù 3
AW - Aruba 2
BH - Bahrain 2
BY - Bielorussia 2
CY - Cipro 2
HN - Honduras 2
IS - Islanda 2
KZ - Kazakistan 2
LA - Repubblica Popolare Democratica del Laos 2
LU - Lussemburgo 2
MA - Marocco 2
MD - Moldavia 2
TH - Thailandia 2
UY - Uruguay 2
AE - Emirati Arabi Uniti 1
AZ - Azerbaigian 1
BA - Bosnia-Erzegovina 1
CO - Colombia 1
GE - Georgia 1
KW - Kuwait 1
LI - Liechtenstein 1
LV - Lettonia 1
MO - Macao, regione amministrativa speciale della Cina 1
MU - Mauritius 1
MX - Messico 1
PA - Panama 1
SI - Slovenia 1
TM - Turkmenistan 1
UG - Uganda 1
VE - Venezuela 1
Totale 50.858
Salva come PNG Salva come JPEG
Città #
Southend 4.046
Fairfield 3.092
Chandler 2.439
Singapore 2.337
Ashburn 1.876
Woodbridge 1.404
Seattle 1.334
Wilmington 1.276
Houston 1.262
Dong Ket 1.151
Cambridge 1.076
Princeton 1.038
Ann Arbor 968
Santa Clara 858
Dublin 790
Boardman 704
Bologna 688
Westminster 374
Nanjing 368
Lomé 365
Beijing 316
Berlin 315
Padova 299
New York 244
Jacksonville 226
Milan 223
Bremen 218
Jinan 208
Sofia 207
San Diego 197
Abidjan 193
Amman 184
Shenyang 180
Redmond 177
Saint Petersburg 177
Turin 173
Helsinki 160
Redwood City 141
Bern 124
Hyderabad 124
Jakarta 118
Brussels 117
Hebei 117
Changsha 115
Nanchang 108
Abeokuta 103
Tianjin 98
Medford 97
Florence 96
Rome 96
Zhengzhou 96
Des Moines 95
Guangzhou 86
Jiaxing 80
Norwalk 75
Los Angeles 73
Olalla 69
Shanghai 69
Dearborn 64
Falls Church 61
Hangzhou 61
Toronto 56
Mülheim 50
Taiyuan 49
Paris 48
London 43
Bühl 40
Haikou 40
Vienna 39
Tokyo 38
Phoenix 36
Washington 36
Casalecchio di Reno 35
Hong Kong 35
Chicago 34
Kunming 34
Ningbo 34
Frankfurt am Main 33
Pune 32
Wuhan 32
Fuzhou 31
Taizhou 31
Fremont 28
Nuremberg 28
Fabriano 27
Lappeenranta 27
Mountain View 27
Lanzhou 26
Munich 26
Parma 26
Salsomaggiore Terme 26
Leawood 25
Mahé 25
Shenzhen 25
Amsterdam 24
Reggio Emilia 24
Boydton 23
Verona 23
Andover 22
Modena 22
Totale 34.686
Salva come PNG Salva come JPEG
Nome #
Incidence of second primary malignancies and related mortality in patients with imatinib-treated chronic myeloid leukemia 334
Aneuploid acute myeloid leukemia exhibits a signature of genomic alterations in the cell cycle and protein degradation machinery 282
A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma. 239
A Specific Pattern of Somatic Mutations Associates with Poor Prognosis Aneuploid Acute Myeloid Leukemia: Results from the European NGS-PTL Consortium 237
Adult "Triple Negative" ACUTE Lymphoblastic Leukemia Genome Wide Characterization 230
18F-FDG PET/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease 217
14-3-3 Binding and Sumoylation Concur to the Down-Modulation of β-catenin Antagonist chibby 1 in Chronic Myeloid Leukemia 210
Circulating calreticulin is increased in myelofibrosis: Correlation with interleukin-6 plasma levels, bone marrow fibrosis, and splenomegaly 200
Bortezomib-based therapy combined with high cut-off hemodialysis is highly effective in newly diagnosed multiple myeloma patients with severe renal impairment 198
Chromothripsis in acute myeloid leukemia: Biological features and impact on survival 194
Peripheral neuropathy induced by subcutaneous bortezomib-based induction therapy for newly diagnosed multiple myeloma. 186
Diagnosis and Treatment of VOD/SOS After Allogeneic Hematopoietic Stem Cell Transplantation 184
Positron emission tomography with computed tomography-based diagnosis of massive extramedullary progression in a patient with high-risk multiple myeloma. 175
Bortezomib and dexamethasone as salvage therapy in patients with relapsed/refractory multiple myeloma: analysis of long-term clinical outcomes 175
A NEW RISK STRATIFICATION STRATEGY IN NEWLY DIAGNOSED MULTIPLE MYELOMA: AN ANALYSIS ON MATURE DATA FROM EUROPEAN CLINICAL TRIALS WITHIN THE HARMONY BIG DATA PLATFORM 175
Prediction of response to primary therapy with thalidomide-dexamethasone (thal-dex) for newly diagnosed multiple myeloma by gene expression profiling (gep) 173
Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. 172
A population-based study of chronic myeloid leukemia patients treated with imatinib in first line 169
Comparison of JAK2V617F-positive essential thrombocythaemia and early primary myelofibrosis: The impact of mutation burden and histology 169
Chibby 1: A new component of β-catenin-signaling in chronic myeloid leukemia 166
Chromothripsis in AML patients: A new mechanism of cancer initiation and progression 164
The Berlin-Frankfurt-Münster protocol for the upfront treatment of aggressive lymphomas: The Bologna experience 164
Response of high-risk MDS to azacitidine and lenalidomide is impacted by baseline and acquired mutations in a cluster of three inositide-specific genes 163
A new risk stratification model (R2-ISS) in Newly Diagnosed Multiple Myeloma: Analysis of Mature Data from 7077 patients collected by European Myeloma Network Within HARMONY Big Data Platform 163
11C-choline vs. 18F-FDG PET/CT in assessing bone involvement in patients with multiple myeloma. 161
The genetic and genomic background of multiple myeloma patients achieving complete response after induction therapy with bortezomib, thalidomide and dexamethasone (VTD) 161
CLINICAL OUTCOMES PREDICTION FOR NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED WITH THALIDOMIDE-DEXAMETHASONE AND AUTOLOGOUS STEM CELL TRANSPLANTATION BY 8-GENE SIGNATURE OF CD138+ PLASMA CELLS 160
Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis 160
A 41-gene signature predicts complete response (CR) to Bortezomib-Thalidomide-Dexamethasone (VTD) as induction therapy prior to autologous stem-cell transplantation (ASCT) in multiple myeloma (MM). 159
A Comparison of Different Staging Systems for Multiple Myeloma: Can the MRI Pattern Play a Prognostic Role? 159
A cell cycle-related genomic and transcriptomic signature distinguish aneuploid and euploid acute myeloid leukemia 159
Cryptic BCR-ABL fusion gene as variant rearrangement in chronic myeloid leukemia: Molecular cytogenetic characterization and influence on TKIs therapy 158
The clonal evolution of two distinct T315I-positive BCR-ABL1 subclones in a Philadelphia-positive acute lymphoblastic leukemia failing multiple lines of therapy: a case report 157
ATP release from chemotherapy-treated dying leukemia cells Elicits an immune suppressive effect by increasing regulatory T cells and Tolerogenic dendritic cells 157
Case Report: A Novel Activating FLT3 Mutation in Acute Myeloid Leukemia 155
Complete remission upon bortezomib-dexamethasone therapy in three heavily pretreated multiple myeloma patients relapsing after allogeneic stem cell transplantation. 153
Thalidomide maintenance in multiple myeloma: certainties and controversies. 152
Bortezomib- and thalidomide-induced peripheral neuropathy in multiple myeloma: clinical and molecular analyses of a phase 3 study. 151
Bromodomain Inhibition Is Effective Against Acute Myeloid Leukemia Cells Under Hypoxia and Induces Genome-Dependent Metabolic Perturbations 151
A VEGF-dependent autocrine loop mediates proliferation and capillarogenesis in bone marrow endothelial cells of patients with multiple myeloma. 150
(90) Y-ibritumomab tiuxetan in patients with extra-nodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) - The Zeno Study 150
Human cord blood-derived platelet lysate enhances the therapeutic activity of adipose-derived mesenchymal stromal cells isolated from Crohn's disease patients in a mouse model of colitis 150
Ascorbic acid inhibits antitumor activity of bortezomib in vivo 149
AZACITIDINE IN HIGH AND LOW RISK MYELODYSPLASTIC SYNDROMES: RETROSPECTIVE EVALUATION OF 57 PATIENTS TREATED WITH 4 DIFFERENT THERAPEUTIC REGIMENS 149
Bortezomib-thalidomide-dexamethasone (VTD) is superior to bortezomib-cyclophosphamide-dexamethasone (VCD) as induction therapy prior to autologous stem cell transplantation in multiple myeloma 148
Glutathione transferase-A2 S112T polymorphism predicts survival, transplant-related mortality, busulfan and bilirubin blood levels after allogeneic stem cell transplantation 148
SETD2 and histone H3 lysine 36 methylation deficiency in advanced systemic mastocytosis 148
Complex chromosomal rearrangements leading to MECOM overexpression are recurrent in myeloid malignancies with various 3q abnormalities 148
CIRCULATING PLATELET AND MEGAKARYOCYTE-DERIVED MICROPARTICLES OF JAK2V617F MUTATED PATIENTS WITH MYELOFIBROSIS ARE DISREGULATED: A NOVEL LIQUID BIOPSY TOOL OF RESPONSE TO RUXOLITINIB? 147
Ceftolozane-Tazobactam Treatment of Hypervirulent Multidrug Resistant Pseudomonas aeruginosa Infections in Neutropenic Patients 147
Thalidomide alone or in combination with dexamethasone in patients with advanced, relapsed or refractory multiple myeloma and renal failure. 145
Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial. 145
First Report of the Gimema LAL1811 Phase II Prospective Study of the Combination of Steroids with Ponatinib As Frontline Therapy of Elderly or Unfit Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia 145
Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib 145
Durability of spleen response affects the outcome of ruxolitinib-treated patients with myelofibrosis: Results from a multicentre study on 284 patients 145
CIRCULATING CD34+ STEM/PROGENITOR CELLS FROM TRIPLE NEGATIVE PATIENTS WITH MYELOFIBROSIS SHOW DIFFERENT NUMBER, GENE EXPRESSION PROFILE AND IN VITRO RESPONSE TO INFLAMMATORY STIMULI AS COMPARED WITH THE JAK2(V617F) MUTATED COUNTERPARTS 145
MEC (mitoxantrone, etoposide, and cytarabine) induces complete remission and is an effective bridge to transplant in acute myeloid leukemia 144
Assessmen of disease ativity in multiple myeloma with FDG-PET imaging 143
A 41-Gene Signature Predicts Complete Response (CR) to Bortezomib-Thalidomide-Dexamethasone (VTD) As Induction Therapy Prior to Autologous Stem-Cell Transplantation (ASCT) in Multiple Myeloma (MM) 143
The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib 143
Inotuzumab ozogamicin is effective in relapsed/refractory extramedullary B acute lymphoblastic leukemia 143
Evaluation of bone disease in multiple myeloma patients carrying the t(4;14) chromosomal translocation. 142
Current and emerging triplet combination therapies for relapsed and refractory multiple myeloma 142
Hypoxia inducible factor-1 alpha as a therapeutic target in multiple myeloma. 141
Mobilized Peripheral Blood versus Cord Blood: Insight into the distinct role of proinflammatory cytokines on survival, clonogenic ability, and migration of CD34+ cells 140
Anti-CD38 and anti-SLAMF7: the future of myeloma immunotherapy 139
Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy 138
Clinical impact of low-burden BCR-ABL1 mutations detectable by amplicon deep sequencing in Philadelphia-positive acute lymphoblastic leukemia patients 137
Circulating Platelet Vs Megakaryocyte-Derived Microparticles Identify Myelofibrosis Patients with JAK2V617F Mutation, High Disease Burden and Ruxolitinib Response 137
Ultra-Deep Sequencing (UDS) Allows More Sensitive Detection of the D816V and Other Kit Gene Mutations in Systemic Mastocytosis 137
Disease-specific derangement of circulating endocannabinoids and n-acylethanolamines in myeloproliferative neoplasms 137
Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study 136
Larger size of donor alloreactive NK cell repertoire correlates with better response to NK cell immunotherapy in elderly acute myeloid leukemia patients 135
Safety and efficacy of daratumumab in dialysis-dependent renal failure secondary to multiple myeloma 135
A real-world efficacy and safety analysis of combined carfilzomib, lenalidomide, and dexamethasone (KRd) in relapsed/refractory multiple myeloma 135
First-line therapy with thalidomide, dexamethasone and zoledronic acid decreases bone resorption markers in patients with multiple myeloma. 134
Contrast enhanced MRI and (18)F-FDG PET-CT in the assessment of multiple myeloma: a comparison of results in different phases of the disease 134
Backtracking BCR-ABL1 Mutants in Philadelphia-Positive Acute Lymphoblastic Leukemia Patients Relapsing on Tyrosine Kinase Inhibitors with Deep Sequencing: Implications for Routine Mutation Testing 134
Prognostic impact of serial measurements of serum-free light chain assay throughout the course of newly diagnosed multiple myeloma treated with bortezomib-based regimens 133
Opposite activation of the Hedgehog pathway in CD138+ plasma cells and CD138-CD19+ B cells identifies two subgroups of patients with multiple myeloma and different prognosis 133
Treatment optimization for Multiple Myeloma: schedule-dependent synergistic cytotoxicity of pomalidomide and carfilzomib in an in vitro and ex-vivo model 133
Circulating megakaryocyte and platelet microvesicles correlate with response to ruxolitinib and distinct disease severity in patients with myelofibrosis 133
Mesenchymal stromal cells from myelodysplastic and acute myeloid leukemia patients display in vitro reduced proliferative potential and similar capacity to support leukemia cell survival 132
Chemotherapy-Induced Tumor Cell Death at the Crossroads Between Immunogenicity and Immunotolerance: Focus on Acute Myeloid Leukemia 132
Bendamustine-rituximab regimen in untreated indolent marginal zone lymphoma: experience on 65 patients 132
The Human Mesenchymal Stromal Cell-Derived Osteocyte Capacity to Modulate Dendritic Cell Functions Is Strictly Dependent on the Culture System 132
Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types. 131
Targeting WEE1 to enhance conventional therapies for acute lymphoblastic leukemia 130
BCR-ABL1 compound mutants: prevalence, spectrum and correlation with tyrosine kinase inhibitor resistance in a consecutive series of Philadelphia chromosome-positive leukemia patients analyzed by NGS 130
Efficacy and safety of ruxolitinib in intermediate-1 IPSS risk myelofibrosis patients: Results from an independent study 129
Extracellular ATP induces apoptosis through P2X7R activation in acute myeloid leukemia cells but not in normal hematopoietic stem cells 129
Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients 129
Thalidomide-dexamethasone as induction therapy before autologous stem cell transplantation in patients with newly diagnosed multiple myeloma and renal insufficiency. 128
Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. 128
Successful mobilization of PBSCs predicts favorable outcomes in multiple myeloma patients treated with novel agents and autologous transplantation 128
Ultra-deep sequencing (uds) allows more sensitive detection of the D816V and other kit gene mutations in systemic mastocytosis 128
Crucial Factors of the Inflammatory Microenvironment (IL-1 beta/TNF-alpha/TIMP-1) Promote Maintenance of the Malignant Hemopoietic Clone of Myelofibrosis By Stimulating the in Vitro Survival/Proliferation/Migration of Circulating CD34+ stem/Progenitor Cells 128
Cap dependent translation contributes to resistance of myeloma cells to bortezomib 127
Genomic characterization of the putative myeloma stem cells clone reveals alterations possibly correlated with the origin of disease. 127
Donor Natural Killer (NK) Alloreactivity Predicts Long-Term Relapse-Free Survival in Acute Myeloid Leukemia Patients Undergoing Immunotherapy with NK Cells 127
Totale 15.504
Salva come PNG Salva come JPEG
Categoria #
all - tutte 155.787
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 155.787
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20206.423 0 0 0 0 0 0 1.447 1.493 1.489 854 527 613
2020/20217.139 1.121 423 178 215 185 332 185 433 839 368 351 2.509
2021/20229.085 815 313 534 706 852 456 205 721 411 685 1.810 1.577
2022/202310.574 1.111 1.517 538 1.445 757 801 360 630 1.759 341 810 505
2023/20243.630 234 526 260 341 301 680 207 288 150 256 213 174
2024/20257.344 618 2.041 1.253 1.083 1.626 722 1 0 0 0 0 0
Totale 52.448